Story
KION Group Shares Decline After Lowering Q3 Profit Outlook
Summary
The German industrial equipment manufacturer warned its third-quarter adjusted EBIT would miss analyst forecasts by approximately 7%, citing weakness in its truck division and higher costs.
Shares of KION Group (ETR:KGX) reversed early gains to close lower on Friday after the industrial equipment manufacturer signaled that its third-quarter profitability will come in below market expectations.
Profit Outlook Lowered
In a pre-close call, KION indicated that its adjusted earnings before interest and taxes (EBIT) for the third quarter would be approximately 7% below consensus analyst estimates. The company attributed the expected shortfall to two primary factors:
- Weaker-than-anticipated profitability in its Industrial Trucks & Services division.
- Higher corporate costs.
Segment Headwinds
AdThe company provided further detail on the challenges facing its key business units. In the industrial truck segment, margins are reportedly being pressured by low capacity utilization amid a period of subdued customer demand.
For its warehouse automation segment, known as Supply Chain Solutions (SCS), KION guided for orders to be flat year-over-year. This figure falls roughly 15% short of consensus forecasts, suggesting that an anticipated recovery in order flow, which can be characteristically lumpy, has not yet materialized in the third quarter.
Market Reaction
The announcement prompted a volatile session for KION's stock. Shares initially rose as much as 1.5% before reversing course to end the trading day down 2.6%. The negative turn reflects investor concerns over the near-term profitability and demand outlook for the logistics and warehouse automation sectors.
Read next
More on Stocks
Anthropic IPO Filing Cites Government Scrutiny as Key Business Risk
In its initial public offering prospectus, artificial intelligence firm Anthropic warned that government actions and perceptions could negatively impact its commercial relationships, even though government contracts make up a small fraction of its revenue.
Biopharma Funding Jumps 56% in September on Public Financing Surge, Mizuho Reports
Biopharmaceutical companies raised $13.0 billion in September, a 56% year-over-year increase, driven by a 272% jump in public-other financing, according to a Mizuho analysis of BioWorld data.
Nvidia Reinstated as Morgan Stanley's Top Semiconductor Pick on Valuation
The investment bank reinstated Nvidia as its top choice in the semiconductor sector, citing an attractive valuation and the company's strong position to capitalize on the growing demand for AI data centers.
AppLovin Stock Slides After Court Denies Injunction Against Unity in Data Dispute
Shares of the mobile technology company fell after a San Francisco court rejected its request for a temporary restraining order against rival Unity Software over alleged data collection practices.